Biaobiao Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Biaobiao Wu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dawei Cui
Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication - Duoliang Qiu
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Fengyun Zhong
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Hao Huang
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Lening Shao
Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication - Tengfei He
The department of general surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China
1 shared publication
Latest Publications
- Open Access
- 11 July 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-15
A pan-cancer analysis for the oncogenic role of cyclin-dependent kinase inhibitor 1B in human cancers
Background: Human health and life are threatened by cancer with high morbidity and mortality worldwide. In many experiments, CDKN1B level is associated with cancer risk, Nevertheless, no pan-cancer analysis has been conducted on CDKN1B in human cancers. Methods: With the help of bioinformatics, a pan-cancer analysis was conducted on the expression levels of CDKN1B in cancer tissues and adjacent tissues from the TCGA, CPTAC and GEO databases. The CDKN1B expression levels in tumor patients was further validated using immunohistochemistry (IHC) and quantitative real-time PCR. Results: In the study, we first investigated the cancer-related roles of CDKN1B’s in 40 tumors with malignancy. The CDKN1B gene encodes the p27Kip1 protein, which can block the production cyclin-dependent kinase (CDK), which is obviously related to the function and survival of cancer cells and alters the prognosis of cancer patients. Furthermore, CDKN1B function requires both protein processing and RNA metabolism. Additionally, the elevated expression of the CDKN1B gene and protein was validated in several cancer tissues from the patients. Conclusions: These results showed that the levels of CDKN1B were considerably different in a number of cancer tissues, offering a potential future target for cancer therapy.
- 11 July 2023
- Published by Springer Nature in Discover Oncology
- Vol. 14 (1) , 1-15
Open AccessA pan-cancer analysis for the oncogenic role of cyclin-dependent kinase inhibitor 1B in human cancers
Background: Human health and life are threatened by cancer with high morbidity and mortality worldwide. In many experiments, CDKN1B level is associated with cancer risk, Nevertheless, no pan-cancer analysis has been conducted on CDKN1B in human cancers. Methods: With the help of bioinformatics, a pan-cancer analysis was conducted on the expression levels of CDKN1B in cancer tissues and adjacent tissues from the TCGA, CPTAC and GEO databases. The CDKN1B expression levels in tumor patients was further validated using immunohistochemistry (IHC) and quantitative real-time PCR. Results: In the study, we first investigated the cancer-related roles of CDKN1B’s in 40 tumors with malignancy. The CDKN1B gene encodes the p27Kip1 protein, which can block the production cyclin-dependent kinase (CDK), which is obviously related to the function and survival of cancer cells and alters the prognosis of cancer patients. Furthermore, CDKN1B function requires both protein processing and RNA metabolism. Additionally, the elevated expression of the CDKN1B gene and protein was validated in several cancer tissues from the patients. Conclusions: These results showed that the levels of CDKN1B were considerably different in a number of cancer tissues, offering a potential future target for cancer therapy.